Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases

医学 德诺苏马布 肿瘤科 泌尿科 置信区间 人口 临床终点 随机对照试验 内科学 骨质疏松症 环境卫生
作者
Shaohua Zhang,Yongmei Yin,Hailin Xiong,Jingfen Wang,Hu Liu,Jun‐Guo Lu,Qingyuan Zhang,Longzhen Zhang,Jin‐Cai Zhong,Jianyun Nie,Kaijian Lei,Hong Wang,Shu Yang,Herui Yao,Huijing Wu,Yu Ding,Xuening Ji,Hua Zhang,Fang Wu,Weimin Xie
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:10 (4): 448-448 被引量:2
标识
DOI:10.1001/jamaoncol.2023.6520
摘要

Importance The bioequivalence of denosumab biosimilar has yet to be studied in a 53-week, multicenter, large-scale, and head-to-head trial. A clinically effective biosimilar may help increase access to denosumab in patients with solid tumor–related bone metastases. Objectives To establish the biosimilarity of MW032 to denosumab in patients with solid tumor–related bone metastases based on a large-scale head-to-head study. Design, Setting, and Participants In this 53-week, randomized, double-blind, phase 3 equivalence trial, patients with solid tumors with bone metastasis were recruited from 46 clinical sites in China. Overall, 856 patients were screened and 708 eligible patients were randomly allocated to receive either MW032 or denosumab. Interventions Patients were randomly assigned (1:1) to receive MW032 or reference denosumab subcutaneously every 4 weeks until week 49. Main Outcomes and Measures The primary end point was percentage change from baseline to week 13 of natural logarithmic transformed urinary N-telopeptide/creatinine ratio (uNTx/uCr). Results Among the 701 evaluable patients (350 in the MW032 group and 351 in the denosumab group), the mean (range) age was 56.1 (22.0-86.0) years and 460 patients were women (65.6%). The mean change of uNTx/uCr from baseline to week 13 was −72.0% (95% CI, −73.5% to −70.4%) in the MW032 group and −72.7% (95% CI, −74.2% to −71.2%) in the denosumab group. These percent changes corresponded to mean logarithmic ratios of −1.27 and −1.30, or a difference of 0.02. The 90% CI for the difference (−0.04 to 0.09) was within the equivalence margin (−0.13 to 0.13); the mean changes of uNTx/uCr and bone-specific alkaline phosphatase (s-BALP) at each time point were also similar during 53 weeks. The differences of uNTx/uCr change were 0.015 (95% CI, −0.06 to 0.09), −0.02 (95% CI, −0.09 to 0.06), −0.05 (95% CI, −0.13 to 0.03) and 0.001 (95% CI, −0.10 to 0.10) at weeks 5, 25, 37, and 53, respectively. The differences of s-BALP change were −0.006 (95% CI, 0.06 to 0.05), 0.00 (95% CI, −0.07 to 0.07), −0.085 (95% CI, −0.18 to 0.01), −0.09 (95% CI, −0.20 to 0.02), and −0.13 (95% CI, −0.27 to 0.004) at weeks 5, 13, 25, 37 and 53, respectively. No significant differences were observed in the incidence of skeletal-related events (−1.4%; 95% CI, −5.8% to 3.0%) or time to first on-study skeletal-related events (unadjusted HR, 0.86; P = .53; multiplicity adjusted HR, 0.87; P = .55) in the 2 groups. Conclusions and Relevance MW032 and denosumab were biosimilar in efficacy, population pharmacokinetics, and safety profile. Availability of denosumab biosimilars may broaden the access to denosumab and reduce the drug burden for patients with advanced tumors. Trial Registration ClinicalTrials.gov Identifier: NCT04812509
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
Patti完成签到,获得积分10
刚刚
1秒前
玩家666发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
HugginBearOuO发布了新的文献求助10
1秒前
科研通AI6.3的应助被魏伯璋采纳,获得10
2秒前
2秒前
2秒前
林强发布了新的文献求助10
2秒前
3秒前
大模型的应助被淡然的水蓝采纳,获得10
3秒前
充电宝的应助被pengg采纳,获得10
4秒前
思源的应助被gfhdf采纳,获得10
4秒前
4秒前
隐形曼青的应助被gfhdf采纳,获得10
4秒前
李健的小迷弟的应助被gfhdf采纳,获得10
5秒前
慕青的应助被开心千青采纳,获得10
5秒前
科研通AI6.3的应助被gfhdf采纳,获得10
5秒前
5秒前
科研通AI6.3的应助被gfhdf采纳,获得10
5秒前
今后的应助被gfhdf采纳,获得10
5秒前
5秒前
YESKY发布了新的文献求助10
5秒前
星辰大海的应助被gfhdf采纳,获得10
6秒前
JamesPei的应助被清秀黄蜂采纳,获得10
6秒前
tang发布了新的文献求助30
6秒前
无花果的应助被gfhdf采纳,获得10
6秒前
陈明明发布了新的文献求助10
6秒前
7秒前
7秒前
潇洒哥暴打黑大帅完成签到,获得积分10
7秒前
sooooly发布了新的文献求助10
7秒前
虚掩的门发布了新的文献求助10
8秒前
大雪纷飞发布了新的文献求助10
8秒前
Lucas的应助被桑榆非晚采纳,获得10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178280
求助须知:如何正确求助?哪些是违规求助? 9569046
关于积分的说明 21802436
捐赠科研通 7773138
什么是DOI,文献DOI怎么找? 3432735
关于科研通互助平台的介绍 2556770
邀请新用户注册赠送积分活动 2478274